Searchable abstracts of presentations at key conferences on calcified tissues

ba0007p175 | (1) | ICCBH2019

Dietary behaviours and compromised nutritional intakes in children with Osteogenesis Imperfecta

Mills Lisa , Clark Robert , Birch Laura , Burren Christine P

Background: Nutrition is a cornerstone of child health. Appropriate nutrient intake contributes to bone health, relevant to conditions of bone fragility. Nutrient intake in chronic conditions can be adversely affected by altered dietary behaviours such as mealtime behaviour and food choice. Dietary behaviour and nutrient intake have not been explored in children with Osteogenesis Imperfecta (OI), the commonest cause of childrenÂ’s bone fragility.Aim:...

ba0006p037 | (1) | ICCBH2017

Early fragility fractures in Zellweger syndrome spectrum – peroxisome dysfunction affecting osteogenesis?

Nicholls Rachel , Pierre Germaine , Chronopoulou Effie , Smithson Sarah F , Offiah Amaka C , Barton John S , Burren Christine P

Background: Peroxisomal Biogenesis Disorders (PBD) is a group of rare metabolic diseases in which peroxisomal function is disrupted. PBD encompasses Zellweger Syndrome Spectrum (ZSS) disorders, which range in severity from classical ZS with severe neurological impairment and markedly reduced life expectancy to Refsum Disease presenting later in childhood. Recent fragility fractures in our ZSS patients in very early childhood prompted case series review.P...

ba0007p71 | (1) | ICCBH2019

Necessity of high dose and prolonged duration denosumab post stem cell transplant for TNFRSF11A osteoclast-poor autosomal recessive osteopetrosis

Taylor-Miller Tashunka , Doss Hemalatha , Weerdenburg Heather , Whiting Sam , Sivaprakasam Ponni , Gassass Adam , Smithson Sarah F , Steward Colin G , Burren Christine P

Background: Hypercalcaemia is a risk following stem cell transplant (SCT) for all types of autosomal recessive osteopetrosis (ARO) due to restored osteoclast differentiation. This can be particularly severe in the osteoclast-poor (OP) form involving the tumour necrosis factor receptor superfamily 11A (TNFRSF11A) gene, encoding RANK. Denosumab, a monoclonal antibody blocking RANK activation, has been described for refractory post-SCT hypercalcaemia in two cases. Our case adds n...